Neurotrope, Inc. Common Stock, also called Neurotrope, is a biopharmaceutical company, which engages in the pre-clinical and clinical development of its product candidates. Read More The company focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company was founded on January 11, 2011 and is headquartered in New York, NY.